Tags

Type your tag names separated by a space and hit enter

Current treatment approaches for Paget's Disease of Bone.
Discov Med. 2010 Sep; 10(52):209-12.DM

Abstract

Paget's Disease of Bone (PDB) is the second most common metabolic bone disease following osteoporosis. PDB is characterized by an increase in bone resorption and bone deposition. For this reason antiresorptives were indicated as the ideal therapy for PDB. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more convenient management of this disorder. However, no firm evidence exists to show that bisphosphonates can prevent the complications of PDB, and further work is needed to evaluate the influence of pharmacological therapy on long-term clinical outcomes, so that clinicians can make better-informed choices about the risks and benefits of treatment. This article will focus on the present status and future pharmacological developments in PDB.

Authors+Show Affiliations

Bone and Mineral Metabolic Unit, Department of Internal Medicine and Careggi Hospital, University of Florence, Florence, Italy. m.brandi@dmi.unifi.it

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20875342

Citation

Brandi, Maria Luisa. "Current Treatment Approaches for Paget's Disease of Bone." Discovery Medicine, vol. 10, no. 52, 2010, pp. 209-12.
Brandi ML. Current treatment approaches for Paget's Disease of Bone. Discov Med. 2010;10(52):209-12.
Brandi, M. L. (2010). Current treatment approaches for Paget's Disease of Bone. Discovery Medicine, 10(52), 209-12.
Brandi ML. Current Treatment Approaches for Paget's Disease of Bone. Discov Med. 2010;10(52):209-12. PubMed PMID: 20875342.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current treatment approaches for Paget's Disease of Bone. A1 - Brandi,Maria Luisa, PY - 2010/9/30/entrez PY - 2010/9/30/pubmed PY - 2011/1/25/medline SP - 209 EP - 12 JF - Discovery medicine JO - Discov Med VL - 10 IS - 52 N2 - Paget's Disease of Bone (PDB) is the second most common metabolic bone disease following osteoporosis. PDB is characterized by an increase in bone resorption and bone deposition. For this reason antiresorptives were indicated as the ideal therapy for PDB. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more convenient management of this disorder. However, no firm evidence exists to show that bisphosphonates can prevent the complications of PDB, and further work is needed to evaluate the influence of pharmacological therapy on long-term clinical outcomes, so that clinicians can make better-informed choices about the risks and benefits of treatment. This article will focus on the present status and future pharmacological developments in PDB. SN - 1944-7930 UR - https://www.unboundmedicine.com/medline/citation/20875342/Current_treatment_approaches_for_Paget's_Disease_of_Bone_ L2 - http://www.discoverymedicine.com/Maria-L-Brandi/2010/09/16/current-treatment-approaches-for-pagets-disease-of-bone/ DB - PRIME DP - Unbound Medicine ER -